Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer

This trial is testing Biolosion — an investigational drug — combined with standard neoadjuvant chemotherapy (chemotherapy given before surgery) for women with triple-negative breast cancer. Triple-negative breast cancer is a more aggressive subtype that does not respond to hormone therapies or HER2-targeted treatments. **You may be eligible if...** - You are a woman aged 18 or older diagnosed with triple-negative breast cancer (confirmed by pathology: ER ≤10%, PR ≤10%, HER2-negative) - Your cancer is stage IIA to IIIC (locally advanced but not yet spread to distant organs) - You have not yet received chemotherapy or targeted therapy for this cancer - A tumor tissue sample is available for testing - Your general health is good (ECOG score 0-2) and you have adequate organ function **You may NOT be eligible if...** - You have received prior chemotherapy or targeted therapy for advanced breast cancer - You have distant metastases - Your expected survival is less than 12 weeks - You have serious underlying health conditions affecting heart, liver, or kidney function Talk to your doctor to see if this trial is right for you.